This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
CAH is a group of rare genetic disorders affecting the adrenal glands, which produce essential hormones like cortisol, aldosterone and androgens. The most common form of CAH, 21-hydroxylase deficiency, disrupts hormone production, leading to cortisol deficiency and an overproduction of androgens. billion in revenue by 2024.
These gut hormones are released in response to nutrient intake and play a crucial role in the incretin effect, which enhances insulin secretion. While GlobalData predicts that Mounjaro and Zepbound will contribute to GLP-1 drugs becoming the best-selling drug class this year, sales of the drugs have been slightly lower than anticipated.
billion, primarily linked to initiating Phase III trials for petrelintide as a stand-alone therapy, with sales-based milestones that could push the total value to $5.3 Amylin, a hormone co-secreted with insulin, plays a key role in regulating appetite by enhancing leptins effects the hormone that signals fullness after eating.
Anti-inflammatory drugs like Restasis and Xiidra are popular treatment options for the condition, but will the emergence of mask-associated dry eye bolster their sales? But if you thought the growing number of patients presenting with mask-associated dry eye would mean higher sales for Restasis, think again.
In this episode, Ayesha discussed the FDA approval of Eli Lilly’s diabetes injection Mounjaro (tirzepatide) for the treatment of adults with type 2 diabetes This is a great advancement in the diabetes space as Mounjaro is a first-in-class medicine that targets the activity of two hormones involved in hunger and blood sugar control (GLP-1 and GIP).
Hidradenitis suppurativa affecting roughly 1% of the population is a chronic skin condition marked by painful boils and abscesses that can significantly disrupt daily life. On March 17, 2025 , Incytes stock closed at $62.01, down 8.62% from the previous close of $67.86.
Related: Eli Lillys Zepbound Approved as First Treatment for Obstructive Sleep Apnea The commercial describes Zepbounds mechanism of action as a dual receptor against that works by activating two naturally occurring hormone receptors in [the] body [GLP-1 and GIP-1]. Late last year, Zepbound brought in $1.26
Since Mounjaro’s May US Food and Drug Administration (FDA) approval, sales of the drug have skyrocketed beyond initial expectations owing to patient demand and a temporary shortage of Novo’s Ozempic. GIP is a metabolic hormone that promotes insulin secretion and also weakly inhibits gastric acid secretion to suppress appetite.
Diabetes remains a critical global challenge, affecting millions of lives and commanding significant attention from the medical, lifesciences and pharmaceutical sectors. Read on to learn more about the top 15 diabetes drugs in 2023, based on 2022 sales statistics. mL subcutaneous solution (2 mg/1.5 billion in Q4 2022.
In the dynamic landscape of oncology therapeutics, understanding the trends and performances of leading drugs is crucial for stakeholders across the healthcare and lifesciences sectors. The top 40 best-selling oncology drugs in 2023, informed by 2022 sales statistics, mark significant milestones in cancer treatment and research.
Mounjaro has thus taken off stronger than expected, surpassing Wall Street sales forecasts during the third quarter. Mounjaro was approved this summer as a Type 2 diabetes treatment and is the first diabetes drug with dual action, targeting two hormones involved in insulin production and appetite (GIP and GLP-1).
Most of the company’s revenue comes from the manufacture and sale of biopharmaceutical products. 5) Ibrance (palbociclib) Ibrance is a chemotherapy drug indicated for hormone receptor positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer. billion in pharmaceutical sales from 2021.
The meteoric rise in the popularity of GLP-1 medications has created a breeding ground for online scams and the sale of unauthorized products,” said LegitScript CEO Scott Roth in a press release.
Pediatric growth hormone deficiency (PGHD) is one such condition, affecting a child’s growth and development. This rare endocrine disorder, characterized by inadequate secretion of growth hormone from the pituitary gland, has profound impacts on physical and sometimes cognitive development.
billion in sales last year, making it the company’s biggest revenue generator in 2020. GLP-1 receptor agonists mimic the action of GLP-1, an intestinal hormone that stimulates the secretion of insulin when blood glucose levels rise. Semaglutide acts by inhibiting glucagon, which is a hormone that increases blood sugar.
TTR is made in the liver and is involved in carrying the thyroid hormone thyroxine (T4) and retinol (vitamin A) to the liver. billion in global sales by 2026. Pfizer has not one but two approved ATTR cardiomyopathy therapies, Vyndaqel and Vyndamax, which secured $2 billion in sales last year.
Oliver Stohlmann’s Corporate Survival Hacks series draws on his experiences of working in local, regional and global lifescience communications to offer some little tips for enjoying a big business career. This post looks at dealing with sudden stress and turning it into positive energy. Visualise success. About the author.
As a leader in lifesciences, diagnostics and applied chemical markets, it is looking to grow its cancer diagnostics pipeline. Resolution has been a leader in the development of NGS-based companion diagnostics (CDx) test development and registration services for precision oncology.
The company’s Supply Center in Berlin will be transformed into a Center of Excellence for parenterals, and the Supply Center in Leverkusen into a Center of Excellence for non-hormonal solids. The Supply Center Bergkamen will become a Center of Excellence for contrast media and hormone products while expanding capacities for therapeutics.
In the dynamic landscape of oncology therapeutics, understanding the trends and performances of leading drugs is crucial for stakeholders across the healthcare and lifesciences sectors. The top 40 best-selling oncology drugs in 2023, informed by 2022 sales statistics, mark significant milestones in cancer treatment and research.
The company is taking steps aimed at strengthening sales growth, profitability and free cash flow. We plan to continue to grow at Pharmaceuticals despite patent expirations and only expect to register a modest decline in sales in 2024,” he said. Speeding up sales growth. through 2023.
Norepinephrine is a hormone and neurotransmitter that helps in alertness and maintaining control in high-stress situations. In 2022, global sales of the drug totalled $115.3 Since its 2021 approval, Qelbree made a significant leap in sales last year due to its expanded approval in adults, having gone from $9.9 million in 2022.
Exact Sciences is pioneering diagnostics that enable personalised medicine for cancer patients. Steven joined Exact Sciences in April 2021 as Vice President Medical, International.
AstraZeneca has won its first-in-class approval for its AKT inhibitor Truqap (capivasertib) in combination with Faslodex (fulvestrant) for treating patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. billion to $1.28
Since its approval in May 2022, Mounjaro sales have hit $1.4 In the first half of 2023, sales of Ozempic and Wegovy rose by 58 percent and 363 percent, respectively. “In Zepbound contains mimetics of the GLP-1 and GIP hormones that regulate appetite and blood sugar. billion in just one year and a quarter. billion for Novo.
They work by mimicking the action of the naturally occurring hormone GLP-1, which is involved in regulating blood sugar and appetite. Access is complex, just like the disease itself is complex,” said Negelle Morris, Novo’s senior VP of cardiometabolic sales. Oprah asked why coverage of weight loss drugs is still limited.
Elinzanetant, a non-hormonal development compound, is currently being investigated in the Phase III clinical development program OASIS for the treatment of vasomotor symptoms during menopause. Every year 47 million women enter menopause, a period where women are at the peak of their life’s activity, personally and professionally.
According to Amgen’s last earnings report , Prolia sales increased 12 percent last year to more than $4 billion, and Xgeva’s jumped five percent from last year to $2.1 Risk factors include aging, hormonal changes, low body weight, low calcium intake and use of certain medications.
About Bayer Bayer is a global enterprise with core competencies in the lifescience fields of health care and nutrition. In fiscal 2022, the Group employed around 101,000 people and had sales of 50.7 The company’s approach to research prioritizes targets and pathways with the potential to impact the way that cancer is treated.
Approximately 80 to 85 percent of these cases were previously considered to be the HER2-negative subtype (which includes hormone receptor positive and triple negative breast cancer), which means the tumors do not make higher than normal amounts of the HER2 protein.
. “Biologics products may contain proteins that control the action of other proteins and cellular processes, genes that control production of vital proteins, modified human hormones, or cells that produce substances that suppress or activate components of the immune system.
The year 2023 was no exception, with several cancer drugs achieving remarkable sales milestones, reflecting their efficacy, expanding indications and the growing global cancer burden. In this blog, we highlight the top 10 cancer drugs to watch in 2024, based on their impressive 2023 sales figures and anticipated market dynamics.
While both semaglutide and tirzepatide have a glucagon-like peptide-1 (GLP-1) agonist component, tirzepatide also acts as an agonist of the gastric inhibitory polypeptide (GIP) hormone; this serves as a differentiator between the two and could explain tirzepatides stronger weight loss effects.
Lifescience industry data analytics company Evaluate Vantage predicts that Mounjaro could bring in $4.9 billion in sales for Lilly by 2026. Trulicity and Jardiance (developed jointly with Boehringer Ingelheim) are Lilly’s other diabetes blockbusters, which totalled sales of more than $10 billion last year.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content